Abstract:
Haemophilia is a congenital bleeding disorder affecting about 1 out of 10,000 people in the general population. Haemophilia is characterized by post-traumatic and spontaneous bleeds, mainly in joints and muscles. Treatment is based on replacement of lacking factors by intravenous infusions when bleeding occurs or preventively. HR-QOL assessment is increasingly recognised as an important health outcome measure in haemophilia, which can help to optimise the treatment and to understand which treatment strategy fits the patients’ needs best. HR-QOL instruments can be distinguished between generic vs. disease-specific measures and instruments for adults and for children. Although the modern management of haemophilia has improved over the last decades patients still can suffer from a burden of their disease regarding clinical (such as treatment complications, presence of inhibitors, pain and arthropathy), psychological (stress and coping, anxiety and depression, stigmatisation and discrimination) and economical aspects. For an adequate assessment of HR-QoL in haemophilic patients validated instruments are necessary. Only in the last 6 years disease-specific HR-QoL instruments have been developed for haemophilic children, namely the European Haemo-QoL, the Canadian CHO-KLAT, the American Quality of Life Questionnaire for Young Patients and for adult patients: the Medtap questionnaire (USA, Canada, Spain and Germany), the South American Hemolatin-QoL, the Italian Haem-A-QoL and the Spanish Hemofilia-QoL. Since treatment of haemophilia can impact on patients’ HR-QoL the assessment of treatment satisfaction becomes quite important providing information for clinical trials and disease management programs. The first haemophilia-specific treatment satisfaction questionnaire for haemophilia patients is described (Hemo-SatA). Development and psychometric testing of these questionnaires is described in detail and revealed that all instruments are reliable and valid instruments which can be used in clinical trials. The choice of an instrument should be based on study-related and instrument-related issues. Results of HR-QoL studies are described concerning treatment effects, severity of the disease, complications and side effects and comparison with the general population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Locus of control is considered an important aspect of personality and can be destinguished between internal locus of control (a person believes that he controls himself and his life) or external locus of control (a person believes that his environment, some higher power or other people control his decisions and his life) (Rotter, 1954).
Abbreviations
- CHQ:
-
Child Health Questionnaire
- GHQ:
-
General Question of the Child Health Questionnaire
- Hem-A-QOL:
-
Hemophilia-specific quality of life instrument for adults
- Hemo-QOL:
-
Hemophilia-specific quality of life instrument for children and parents
- Hemofilia-QOL:
-
Hemophilia-specific quality of life instrument for adults
- Hemolatin-QOL:
-
Hemophilia-specific quality of life instrument for adults
- Hemo-SatA :
-
Hemophilia-specific treatment satisfaction questionnaire for adults and parents
- HIV:
-
Human Immune Deficiency Virus
- HRQOL:
- KINDL:
-
Generic quality of life questionnaire for children
- MCS:
-
Mental Component Summary Score of the SF-36
- Medtap:
-
Hemophilia-specific quality of life instrument for adults
- PCS:
-
Physical Component Summary Score of the SF-36
- PedsQL:
-
Generic quality of life questionnaire for children
- QOL:
-
Quality of life
- SF-36:
-
Generic Quality of Life questionnaire for adults (Short-form 36)
- TS:
-
Treatment Satisfaction
References
Aledort L, Haschmeyer R, Pettersson H. (1994). J Intern Med. 236: 391–339.
Aledort LM. (2000). Haemostasis. 30(6): 333–336.
Arranz P, Remor E, Quintana M, Villar A, Diaz JL, Moreno M, Monteagudo J, Ugarriza A, Soto I, Perez R, Chacon J, Garcia-Luaces M, Cid A, Balda I, Lopez MF, Gutierrez MJ, Martinez E, Marrero C, Prieto M, Sedano C, Vaca R, Altisent C, Hernandez-Navarro F, Hemofilia-QOL Group. (2004). Hemophilia. 10: 376–382.
Aznar J, Magall M, Querol F, Gorina E, Tusell J. (2000). Hemophilia. 6: 170–176.
Barlow JH, Stapley J, Ellard DR. (2007) Patient Educ Couns. 68(3): 235–242.
Barrowcliffe TW. (2004). Hemophilia. 10(Suppl 4): 109–114.
Barr RD, Saleh M, Furlong W, Horsman J, Sek J, Pai M, Walker I. (2002). Am J Hematol. 71(3): 152–160.
Beeton K, Neal D, Watson T, Lee CA. (2007). Hemophilia. 13(5): 570–579.
Berntorp E. (1995). Hemophilia 1(Suppl. 1): 3–7.
Berntorp E, Astermark J, Björkman S, Blanchette VS, Fischer K, Giangrande PL, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C. (2003). Hemophilia 9(Suppl 1): 1–4.
Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peak I, Rickard K, et al. (1995). Bull World Health Organ. 73(5): 691–701.
Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dimichele D, Escuriola C, Hay CR, Hoots WK, Leissinger CA, Negrier C, Oldenburg J, Peerlinck K, Reding MT, Hart C. (2006). Hemophilia. 12(Suppl 6): 1–7.
Björkman S. (2003). Hemophilia. 9(Suppl 1): 101–8.
Bolton-Maggs PH. (2006). Br J Haematol. 132(6): 671–682.
Bottos AM, Zanon E, Sartori MT, Girolami A. (2007). Hemophilia. 13(3): 305–310.
Bowling A. (1991). “Measuring Health. A Review of Quality of Life Measurement Scales”, Milton Keynes. Open University Press: Philadelphia.
Bowling A. (2001). “Measuring disease. A review of disease-specific quality of life measurement scales”, Open University Press, Buckingham.
Brown P. (2007). Hemophilia. 13(Suppl 5): 33–40.
Bullinger M. (1991). Thero Surg. 6: 143–149.
Bullinger M, Mackensen S, The Haemo-QOL Group. (2003). J Pediatr Haematol Oncol. 25(Suppl. 1): 64–67.
Bullinger M, von Mackensen S, Fischer K, Khair K, Petersen C, Ravens-Sieberer U, Roccino A, Sagnier P, Tusell J, van den Berg M, Vicariot M. (2002). Hemophilia. 8(Suppl. 2): 47–54.
Bussing R, Burket RC. (1993). J Am Acad Child Adolesc Psychiatry. 32(3): 562–567.
Canclini M, Saviolo-Negrin N, Zanon E, Bertoletti R, Girolami A, Pagnan A. (2003). Hemophilia. 9(5): 619–624.
Cella DF, Tulsky DS. (1993). Oncology. 29–38.
Centers of Disease Control. (1982). “Update on Acquired Immune Deficiency Syndrome (AIDS) Among Patients with Hemophilia”, MMWR Wkly. 31: 644–652.
Choo KH, Gould KG, Rees DJG, Brownlee GG. (1982). Nature. 299: 178–80.
Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M. (2007). Blood. 110(3): 815–25.
Donadel-Claeyssens S. On behalf of the European Paediatric Network for Hemophilia Management. (2006). Hemophilia. 12: 124–127.
Drotar D, Agle DP, Eckl CL, Thompson PA. (1997). J Pediatr Psychol. 22(1): 1–14.
Ehrlich HJ, Henzl MJ, Gomperts ED. (2002). Hemophilia. 8: 83–90.
Eiser C, Morse R. (2001). Arch Dis Child. 84: 205–211.
Evatt BL. (2005). Semin Thromb Hemost. 31(5): 489–494.
Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, Hoots WK, Buchanan GR, Manco-Johnson MJ, Rivard GE, Miller KL, Geraghty S, Maahs JA, Stuart R, Dunham T, Navickis RJ. (2004). Hemophilia. 10(5): 629–48.
Fischer K, Astermark J, van der Bom J, Ljung R, Berntorp E, Grobbees D, van den Berg HM. (2002). Hemophilia. 8: 753–760.
Flood E, Szende A, Rentz A, Gorina E, Larson P, Bullinger M, Schramm W, Wasserman J, Leidy NK. (2003). Journal of Thrombosis and Haemostasis. 1(suppl. 1): abstract number P0657.
Freiburghaus C, Berntorp E, Ekman M, Gunnarsson J, Kjellberg BM, Nilsson IM. (2002). Hemophilia. 4: 16–20.
Furie B, Limentani SA, Rosenfield CG. (1994). Blood. 84: 3–9.
Giangrande PL. (2003). Hemophilia. 9(Suppl 1): 50–4.
Giannelli F, Green PM. (1996). Bailliere’s Hematol. 9: 211–228.
Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. (1984). Nature. 312: 326–30.
Gringeri A, Mannucci PM. Italian Association of Hemophilia Centres. (2005). Hemophilia. 11(6): 611–619.
Gringeri A, Mantovani LG, Scalone L, Mannucci PM. (2003). Blood. 102: 2358–2363.
Gringeri A, Mantovani L, von Mackensen S. (2006). Hemophilia: 12(Suppl. 3): 22–29.
Gringeri A, von Mackensen S. (2008). Hemophilia. 14(Suppl 3): 19–25.
Gringeri A, von Mackensen S, Auerswald G, Bullinger M, Perez Garrido R, Kellermann E, Khair K, Lenk H, Vicariot M, Villar A, Wermes C. For the Haemo-QOL Study. (2004). Hemophilia. 1, 10(Suppl. 1): 26–33.
Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. (2008). Hemophilia. 1: 1–6.
Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. (2006). Br J Haematol. 133(6): 591–605.
Hay C, Recht M, Carcao M, Reipert B. (2006). Semin Thromb Hemost. 32(Suppl 2): 15–21.
Hilgartner M, Knatterud GL, The FEIBA Study Group. (1983). Blood. 61: 36–40.
Holahan CJ, Moos RH. (1987). J Abnorm Psychol. 96: 3–13.
Jadhav M, Warrier I. (2000). Semin Thromb Hemost. 26(2): 205–8.
Jones QJ, Garsia RJ, Wu RT, Job RF, Dunn SM. (1995). J Psychosom Res. 39(5): 597–608.
Karimi M, Peyvandi F, Siboni S, Ardeshirim R, Gringeri A, Mannucci PM. (2004). Hemophilia. 10(4): 367–369.
Key NS, Negrier C. (2007). Lancet. 370(9585): 439–48.
Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz-Körholz C, Kreuz W. (1999). Eur J Pediatr. 158: 162–5.
Komvilaisak P, Connolly B, Naqvi A, Blanchette V. (2006). Hemophilia. 12(Suppl 6): 87–93.
Kraus EM, Brettler DB. (1988). Am J Med Genet. 31(2): 259–267.
Lacey L. (2002). Pathophysiol Haemost Thromb 32:(suppl 1):29–32.
Liesner RJ, Khair K, Hann IM. (1996). Br J Haematol. 92: 973–978.
Ljung R. (2007). Br J Haematol. 138(5): 580–586.
Ljung R, Petrini P, Nilsson IM. (1990). Acta Paediatr Scand. 79: 196–200.
Lloyd Jones M, Wight J, Paisley S, Knight C. (2003). Hemophilia. 9: 464–520.
Lusher J, Ingerslev J, Roberts H, Hedner U. (1998). Blood Coagul Fibrinolysis. 9: 119–28.
Magli-Barioz D, Ounnoughène N, Paugy P, Quarrè MC, Vassilief D, Lopez I, Goudemand J, Negrier C, Assogba U, Driss F, Dumont MA, Molho P. (2004). Hemophilia. 10(5): 572–581.
Manco-Johnson M, Morrissey-Harding G, Edelman-Lewis B, Oster G, Larson P. (2004). Hemophilia. 10: 34–41.
Mann KG. (1999). Thromb Haemost. 278: 9370–7.
Mannucci PM. (2003). J Thromb Haemos. 1: 1349–1355.
Miller R, Sabin C, Goldman E, Clemente C, Sadowski H, Lee CA. (2000). Psychol Health Med. 5: 3–12.
Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. (1999). Hemophilia. 5(6): 378–85.
Molho P, Rolland N, Lebrun T, Dirat G, Courpied J, Croughs T, Duprat I, Sultan Y. (2000). Hemophilia. 6: 23–32.
Monat A, Lazarus RS. (1977). “Stress and Coping: An Anthology”, Columbia University Press, New York, pp.6.
Morfini M. (2003). Hemophilia. 9(Suppl 1): 94–9.
Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. The members of the French FEIBA study group. (1997). Thromb Haemost. 77: 1113–1119.
Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. (1992). J Intern Med 232(1): 25–32.
Pollak E, Mühlan H, von Mackensen S, Bullinger M. the Haemo-QOL Group. (2006). Hemophilia. 12: 384–392.
“Prevention and Control of Hemophilia: Memorandum from a Joint WHO/WFH Meeting”. (1991). Bull World Health Organ. LXIX. 1: 17–26.
Prowse C, Ludlam CA, Yap PL. (1997). Vox Sang. 72(1): 1–10.
Remor E. (2005). Revista Interamericana de Psicología/ Interamerican J Psychol. 39(2), 211–220.
Remor E, Arranz P, Quintana M, Villar A, Jimenez-Yuste V, Diaz JL, Del Rincon C, Marrero C, Moreno M, Lucia JF, Martinez E, Soto I, Sedano C, Gonzalez-Boullosa R, Prieto M, Garcia-Luaces M, Hernandez-Navarro F, in representation of the Hemofilia-QOL Project Group. (2005). Hemophilia. 11: 603–610.
Remor E, Young NL, von Mackensen S, Lopatina EG. (2004). Hemophilia. 10(Suppl. 4): 30–34.
Rentz A, Flood E, Altisent C, Bullinger M, Klamroth R, Garrido RP, Scharrer I, Schramm W, Gorina E. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14(5): 1023–1034.
Report of a Joint WHO/WFH/ISTH Meeting. (2002). “Delivery of Treatment for Hemophilia”, World Health Organization. London, UK.
Rizza CR. (1984). Scand J Haematol. 40(Suppl.33): 187–193.
Roberts HR, Monroe DM. 3rd, Hoffman M. (2004). Semin Hematol. 41(suppl 1): 101–108.
Rosendaal FR, Smit C, Varekamp I, Bröcker-Vriends AH, van Dijck H, Suurmeijer TP, Vandenbroucke JP, Briët E. (1990). J Intern Med. 228: 663–640.
Rosendaal G, van der Berg HM, Lafeber FPJG, Bijlsma JWJ. (2000). “Blood-induced joint damage: an overview of musculoskeletal research in hemophilia”, In: Rodriguez-Merchan EC, Goddard NJ, Lee CA (eds.) “Muskuloskeletal Aspects of Hemophilia”, Blackwell Science Ltd, Oxford, UK, pp. 18–26.
Rotter JB. (1954). “Social Learning and Clinical Psychology”. Prentice-Hall.New York
Royal S, Schramm W, Berntorp E, Giangrande P, Gringeri, A, Ludlam C, Kroner B, Szucs T, for the European hemophilia economics study group. (2002). Hemophilia. 8: 44–50.
Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muça-Perja M, Mannucci PM. (2003). Br J Haematol. 123(3): 502–506.
Santagostino E, Gringeri A, Mannucci PM. (1999). Br J Haematol. 104: 22–26.
Saviolo-Negrin N, Cristante F, Zanon E, Canclini M, Stocco D, Girolami A. (1999). Hemophilia 5(1): 63–68.
Schick M, Stucki G, Rodriguez M, Meili E, Huber E, Michel B, Bruhlmann P. (1999). Clin-Rheumatol. 18: 468–472.
Schoenmakers M, Gulmans V, Helders P, van den Berg HM. (2001). Hemophilia. 7: 293–298.
Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, Gringeri A, Berger K, Szucs T. For the European hemophilia economic study group. (2002). “Clinical outcomes and resource utilization associated with hemophilia care in Europe”, Hemophilia. 8: 33–43.
Shapiro A, Donfield S, Lynn H, Cool V, Stehbens J, Hunsberger S, Tonetta S, Gomperts E.D. Academic Achievement in Children with Hemophilia Study Group. (2001). Pediatrics. 108: 6:e105.
Solovieva S. (2001). Hemophilia. 7: 53–63.
Spielberger CD. (1972). “Anxiety: Current trends in theory and research”, Academic Press. New York, N.Y.
Sung L, Young NL, Greenberg ML, McLimont M, Samanta T, Wong J, Rubenstein J, Ingber S, Doyle JJ, Feldman BM. (2004). J Clin Epidemiol. 57(11): 1161–1166.
Szucs TD, Offner A, Schramm W. (1996). Hemophilia. 2: 211–217.
Tedgård U, Ljung R, McNeil TF. (1999). Br J Haematol. 106(2): 421–426.
Teitel J, Berntorp E, Collins P, D’Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissinger C, Monahan P,Young G. (2007). Hemophilia. 13(3): 256–63.
The WHOQOL Group. Study protocol for the World Health Organization. Project to develop a Quality of Life assessment instrument (WHOQOL) (1993). Qual Life Res. 2: 153–159.
Triemstra AH, Van der Ploeg HM, Smit C, Briët E, Adèr HJ, Rosendaal FR. (1998). Soc Sci Med. 47(5): 581–593.
Trippoli S, Vaiani M, Linari S, Longo G, Morfini M, Messori A. (2001). Haematologica. 86: 722–728.
Troisi CL, Hollinger FB, Hoots WK, Contant C, Gill J, Ragni M, Parmley R, Sexauer C, Gomperts E, Buchanan G. (1993). Blood. 81: 412–418.
Vermilen J, Peerlink K. (1994). Vox Sang. 84 (Suppl 4): 8–11.
von Mackensen S. (2007). Hemophilia. 13(2): 38–43.
von Mackensen S, Bullinger M, The Haemo-QOL Group. (2004). Hemophilia. 10(Suppl. 1): 17–25.
von Mackensen SV., Gringeri A. (2005). “Quality of Life in Hemophilia”. In: Lee CA, Berntorp EE, Keith Hoots W. (eds.) Textbook of Hemophilia. Blackwell Publishing Ltd. Oxford, UK, pp. 345–350.
von Mackensen S, Gringeri A, Mantovani L, Skovlund SE, Mannucci PM. (2002). Blood. 100(11) (Abstract).
von Mackensen S, Gringeri A, Mantovani L, Skovlund S, Santoni L, Tagliaferro A, Tagariello G, Ciavarella N, Iorio A. (2004). Hemophilia. 10(Suppl. 3): 126 (Abstract).
von Mackensen S, Gringeri A, Ravera S, (2005). the Haem-A-QOL Group. Haematologica. 90(Suppl. 2): 116–117 [Abstract 0290].
von Mackensen S, Gringeri A, Santoni L, Tagliaferro A, Tagariello G, Ciavarella N, Iorio A, Molinari C. (2004). Blood. 104(11): 2214 [Abstract].
von Mackensen S, Gringeri A, Scalone L, Mantovani L, (2005). the COCHE Study Group. Haematologica. 90(Suppl 2): 310. [Abstract 0778].
von Mackensen S, Scalone L, Ravera S, Mantovani L, Gringeri A. For the COCHE Study Group. (2007). “Quality of Life Assessment in Adult Patients with Hemophilia – Results of the COCHE Study”, Oral presentation at the annual congress of the Society of Thrombosis and Haemostasis Research. Dresden, 21–25 February 2007, FV19.
von Mackensen S, Scalone L, Ravera S, Mantovani L, Gringeri A, (2005). for the COCHE Study Group. Value Health 8(6): A127 [Abstract PHM5].
von Mackensen S, Siboni SM, Gringeri A, Tradati F, Franchini M, Tagliaferro A, Mannucci PM. (2008). Hemophilia. 14(s2): 127 [Abstract 22 S 01].
Walsh M, Macgregor D, Stuckless S, Barrett B, Kawaja M, Scully MF. (2008). J Thromb Haemost 6(5): 755–761.
Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. (1997). A J Manag Care. 3: 579–594.
White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. (2001). Thromb Haemost 85: 560.
Wiener LS, Vasquez MJ, Battles HB. (2001).J Pediatr Psychol. 26(6): 353–358.
Wight J, Paisley S. (2003). Hemophilia 9(4): 418–35.
Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. (2005). Qual Life Res 14(2): 285–295.
Yi M, Kim WO, Kang HS. (2003) Taehan Kanho Hakhoe Chi. 33:(7)875–884.
Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. (2006). Pediatr Blood Cancer. 47: 305–311.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Mackensen, S.V., Gringeri, A. (2010). Quality of Life in Hemophilia. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_112
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_112
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine